4dmt announces positive long-term data from phase 1/2 prism clinical trial in wet amd supporting 4d-150's potential as a backbone therapy with consistent and durable benefit over multiple years

Emeryville, calif., nov. 06, 2025 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive interim 1.5- to 3.5-year data from the phase 1/2 prism clinical trial evaluating 4d-150 in patients with wet age-related macular degeneration (wet amd). the data will be presented in detail at an upcoming scientific conference.
AMD Ratings Summary
AMD Quant Ranking